We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)


Second agreement helps validate capabilities

Lighthouse | 13 August 2019

Hutchison China MediTech

Carrying momentum into H219

Update | 13 August 2019


All eyes on Q3 following a record Q2

Update | 31 July 2019


Ideally placed to sustain growth

Update | 17 July 2019

Mereo BioPharma

Accelerated approval path for NAVI

Lighthouse | 16 July 2019


Ground prepared for an important period

Lighthouse | 01 July 2019

Hutchison China MediTech

Secondary ADS offering trims CK Hutchison stake

Lighthouse | 28 June 2019


Private placement to support randomised Phase II trials

Update | 19 June 2019

Hutchison China MediTech

Surufatinib on track for potential 2020 China approval

Update | 18 June 2019

Hutchison China MediTech

Impressive data means SANET-ep trial stopped early

Lighthouse | 14 June 2019
1 2 3 4 5 6 7 8 9 10 11 12
119 results found.